Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.

[1]  R. Sakai,et al.  Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines , 2002, Oncogene.

[2]  G. Brodeur Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[3]  筬島 裕子,et al.  Biological role of anaplastic lymphoma kinase in neuroblastoma , 2006 .

[4]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[5]  Anne Vincent-Salomon,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[6]  J. Trent,et al.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.

[7]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[8]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[9]  Isabelle Janoueix-Lerosey,et al.  Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. , 2005, Cancer letters.

[10]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[11]  Rongshi Li,et al.  Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy , 2008, Medicinal research reviews.

[12]  K. Pulford,et al.  Expression of the ALK tyrosine kinase gene in neuroblastoma. , 2000, The American journal of pathology.

[13]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[14]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[15]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[16]  Stevan R. Hubbard,et al.  Juxtamembrane autoinhibition in receptor tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[17]  A. R.,et al.  Review of literature , 1951, American Potato Journal.

[18]  G. Inghirami,et al.  The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination , 2008, Nature Medicine.

[19]  L. Shun An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms , 2010 .

[20]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[21]  O. Delattre,et al.  Characterization of amplicons in neuroblastoma: High‐resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes , 2008, Genes, chromosomes & cancer.

[22]  Stefan Fröhling,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[23]  C. Preudhomme,et al.  Cooperating gene mutations in acute myeloid leukemia: a review of the literature , 2008, Leukemia.

[24]  Familial neuroblastoma: a complex heritable disease. , 2003, Cancer letters.

[25]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[26]  H. Satoh,et al.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Griffin,et al.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.